Takeda and Maverick Therapeutics have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. The $125 million of funding includes an upfront option, equity and research and development funding payments, and provides Takeda the exclusive right to purchase Maverick after five years. Maverick was founded in 2016. “We believe that this collaboration validates Maverick’s approac...